The American Association for Cancer Research urged FDA to regulate high-risk laboratory-developed tests, a category of assays that has escaped scrutiny because of loopholes in the regulatory process.
Following our discovery that my wife's occult uterine cancer was morcellated using a gynecological power morcellator, we initiated a vigorous campaign to protect others from this avoidable harm. It is now increasingly clear that one in 350-500 women with symptomatic fibroids have occult or missed uterine cancer lurking in what a majority of gynecological surgeons have assumed to be benign tumors.
Stand Up To Cancer, a non-profit cancer group that conducts televised fundraising events, raised over $109 million last weekend.
Is the new National Clinical Trials Network set up for success or heading for failure?
The Cancer Prevention and Research Institute of Texas last month awarded 101 new grants: 84 for research, 15 for prevention and two for product development.
Jessie Gruman, founder and president of the Center for Advancing Health since 1992, died July 14. She was 60.
The American Association for Cancer Research and the American Society of Clinical Oncology urged the FDA to regulate all tobacco products, including e-cigarettes.
The College of American Pathologists published recommendations for active surveillance of patients with prostate cancer.
NCI launched another in a series of targeted treatment trials referred to as the AdjuvantLungCancer EnrichmentMarkerIdentification andSequencingTrial.
A German company that makes devices now under FDA scrutiny for their potential to spread sarcoma threatened legal action against the U.S. surgeon whose wife's cancer cells were disseminated during routine surgery to remove fibroids.
